Monocyte-derived tissue factor contributes to stent thrombosis in an in vitro system  by Palmerini, Tullio et al.
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onocyte-Derived Tissue Factor Contributes
o Stent Thrombosis in an In Vitro System
ullio Palmerini, MD,* Barry S. Coller, MD,‡ Vittorio Cervi, BSC,* Luciana Tomasi, BSC,*
ntonio Marzocchi, MD,* Cinzia Marrozzini, MD,* Ornella Leone, MD,† Milena Piccioli, BSC,†
ngelo Branzi, MD*
ologna, Italy; and New York, New York
OBJECTIVES This study evaluated the role of circulating tissue factor (TF) in mediating thrombus
formation on stents in an in vitro model of stent perfusion.
BACKGROUND The traditional view of coagulation has recently been challenged by the demonstration that
TF is present in circulating blood. The potential contribution of this intravascular pool of TF
to thrombus formation on stents is not known.
METHODS Coronary stents were placed in parallel silicone tubes connected to a roller pump that was set
to pump blood at a flow rate of 10 ml/min. Stents were then exposed to heparinized blood
from healthy volunteers for 120 min.
RESULTS The presence of the stent in the circuit caused a significant increase in monocyte TF
expression, but only monocytes with attached platelets stained positive for TF. Thrombi
formed on stents and the thrombi stained positive for TF. Pretreatment of blood with a
monoclonal antibody against TF (cH36) caused a 56% reduction in 125I-fibrin(ogen)
deposition on stents compared with controls (p  0.002). Monocyte depletion of blood
reduced 125I-fibrin(ogen) deposition by 45% (p  0.01) and TF staining in the thrombus by
83% (p  0.01). Pretreatment of blood with a monoclonal antibody against P-selectin
reduced 125I-fibrin(ogen) deposition by 24% (p  0.04). Perfusion of stents with leukocyte-
reduced platelet-rich plasma (PRP) produced small thrombi and treatment of PRP with
cH36 reduced 125I-fibrin(ogen) deposition by 43% (p  0.01).
CONCLUSIONS Circulating TF plays a pivotal role in thrombus formation on stents. Monocytes appear to be
the main, but not only, source of TF depositing in the thrombus. (J Am Coll Cardiol 2004;
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.07.02844:1570–7) © 2004 by the American College of Cardiology Foundation
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aissue factor (TF) is a transmembrane glycoprotein that
riggers the extrinsic pathway of the coagulation cascade.
issue factor binds to factor VII/VIIa and the resulting
omplex activates factor IX and X, with the subsequent
eneration of thrombin and deposition of fibrin (1,2).
The classic view of coagulation implies that upon disrup-
ion of the vessel wall, TF sequestered in the adventitia is
xposed to the flowing blood, with the consequent activa-
ion of coagulation and thrombus formation (3). This view
f coagulation has been challenged by the discovery that TF
s also present in circulating blood in association with small
ipid vesicles that can bind to platelet aggregates that form
n collagen-coated surfaces in vitro (4). The precise source
f these vesicles has not, however, been identified.
Coronary stents have improved the outcome of patients
ndergoing percutaneous coronary interventions (5). Nev-
rtheless, around 1% of patients may experience subacute
hrombosis of the stent, and as many as 37% may have an
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ccepted July 12, 2004.ncrease in creatine phosphokinase muscle brain isoenzyme
elease after stent placement (6).
A better understanding of the thrombotic mechanisms
riggered by stents may provide new therapeutic approaches
o prevent clinical events following coronary interventions.
In this study we found that circulating TF plays a crucial
ole in mediating thrombus formation on stents in an in
itro model of stent perfusion. Moreover, monocytes were
dentified as a main source of the TF that contributed to
tent thrombus formation.
ETHODS
lood sample collection and preparation of monocyte-
educed blood. Blood samples (30 ml) were collected in a
yringe containing 10 IU of unfractionated heparin
Epsoclar; Biologici Italia, Milano, Italy) from healthy
olunteers who were not taking medication and who were
n average 30 years of age (range 23 to 35 years ). Activated
lotting time was measured with a HEMOCRON 401
Cremascoli, Iris, Milano, Italy) and adjusted to 180 to
30 s by adding additional heparin (range 2.5 to 5 IU).
To prepare platelet-rich plasma (PRP), blood was cen-
rifuged at 90 g  10 min at 22°C and the platelet count
djusted to 200,000/l. To reduce the leukocyte content of
he PRP, it was passed through a filter of precision-woven
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nc., Carmel, New York). This process virtually abolished
eukocyte contamination, as judged by flow cytometry.
latelet-poor plasma (PPP) was prepared by further centrif-
gation of the remaining blood at 2,000 g  10 min.
In some experiments blood was reacted with superpara-
agnetic polystyrene beads (Dynabeads M-450 CD 14;
ynal Biotech, Oslo, Norway) coated with a primary
onoclonal antibody (Mab) specifically for the CD14
onocyte membrane marker by diluting 2.5 ml of blood
ith an equal volume of buffer (phosphate-buffered saline)
137 mM NaCl, 1.5 mM KH2PO4, 8 mM Na2HPO4, 2.7
M KCl, pH 7.4) and then adding 50 l beads/ml of
lood. The blood and beads were placed on a mixer (Dynal
itoech) at 4°C for 60 min and then the beads and attached
ells and/or other material were separated using a magnetic
article concentrator (Dynal Biotech) for 5 min. The
emaining blood was analyzed for monocyte depletion by
ow cytometry.
Depending on the experiment, 5 ml of whole blood,
onocyte-reduced blood (MRB), PRP, or PPP was placed
nto polystyrene tubes and incubated for 10 min with 25
g/ml of 125I-fibrin(ogen) (Amersham Biosciences,
ilano, Italy), and with saline, 200 g/ml of cH36, a
himeric Mab against TF (kindly supplied by Sunol Mo-
ecular Corporation, Miramar, Florida), or 60 g/ml of
nti-P-selectin antibody (9E1, R & D Systems, Minneap-
lis, Minnesota). In preliminary experiments, cH36 (250
g/l) was incubated with recombinant TF (Hemoliance,
nstrumentation Laboratory, Milano, Italy) and then the
F was used in a prothrombin assay. Compared with the
2-s control, incubation with cH36 resulted in prolongation
f the prothrombin time to 82 s. After taking 5 l of the
ample to measure the 125I-specific activity, blood or plasma
rom each tube was transferred to the corresponding silicone
ubing of the flow system.
This protocol was approved by the local ethics committee
nd informed consent was obtained from all the blood
onors.
low system and experimental design. Twenty-three-
illimeter long Tetra Multilink stents (kindly supplied by
uidant, Temecula, California) were inserted and then
eployed in silicone tubing (3 mm inner diameter) (Gilson
talia, Milano, Italy) by inflating the balloon at 14 atm for
0 s. The silicone tubing was then connected to a roller
ump (Minipuls 3; Gilson, Villers, France), which was set
Abbreviations and Acronyms
IOD  integrated optical density
Mab  monoclonal antibody
MRB monocyte-reduced blood
PPP  platelet-poor plasma
PRP  platelet-rich plasma
TF  tissue factoro pump blood at a flow rate of 10 ml/min, with a theoretically calculated shear rate of 64 s1. The circuit
as then closed using a silicone connector and the perfusion
erformed for 120 min. The temperature was kept stable at
7°C by a water bath.
The study consisted of three different sets of experiments.
he first set (group 1) consisted of 10 experiments; in each
ase, four silicone tubing circuits were perfused in parallel:
ircuit A contained saline-treated blood with no stent and
erved as a control, whereas circuits B, C, and D all
ontained stents and the blood was pretreated with saline,
H36, or 9E1, respectively.
The second set (group 2) consisted of six experiments;
n each case four perfusions were performed in parallel:
ircuit A was the control as before, whereas in the
emaining three perfusion stents were exposed to whole
lood (circuit B), MRB (circuit C), or MRB pretreated
ith cH36 (circuit D).
The third set (group 3) consisted of six experiments; in
ach case five perfusions were performed in parallel: circuit
contained saline-treated PRP with no stent and served as
control, whereas in the remaining four perfusion stents
ere exposed to PPP (circuit B), PPP  cH36 (circuit C),
RP (circuit D), and PRP  cH36 (circuit E).
adioactivity measurements. At the end of the perfusion
he stents were recovered from the tubing and their 125I-
adioactivity measured using a gamma spectrometer (Can-
erra Industries, Meriden, Connecticut). In some experi-
ents, in addition to thrombi on the stent, thrombi were
ound free in the tubing; these thrombi were added to the
tent thrombi before measuring the radioactivity.
low cytometry. Mab to CD45 (phycoerythrin [PE]-
abeled), CD14 (PE, fluorescein isothiocyanate [FITC],
nd allophycocyanin-labeled), and CD42b (PE-labeled), as
ell as isotype controls, were from Pharmingen (San Diego,
alifornia). Anti-TF (FITC-labeled) Mab was from
merican Diagnostica (Greenwich, Connecticut). Samples
ere analyzed using a FACSCalibur flow cytometer (Bec-
on Dickinson, San Jose, California) equipped with
ELLQuest analysis software (Becton Dickinson). In stud-
es involving more than one labeled antibody, compensation
as performed using Calibrite beads and FACSComp
oftware (Becton Dickinson).
Monocyte TF expression was determined in the first set
f experiments at baseline and at the end of the perfusion as
reviously described by Lindmark et al. (7). In brief,
onocytes were identified by gating on CD14-positive
ells, and TF positivity was defined as a fluorescence
ntensity greater than a threshold set at the upper 2% value
sing the isotype control. In two cases, triple staining was
erformed using an anti-CD14 (APC) Mab, an anti-TF
FITC) Mab, and an anti-CD42b (PE) Mab, which en-
bled an assessment of the correlation between platelet-
onocyte aggregates and monocyte TF expression. Mono-
ytes were identified by both their characteristic scatter
roperties and CD14 positivity, and thereafter subjected to
wo-color analysis using TF-FITC and CD42b-PE.
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D14 beads, leukocytes were identified by their character-
stic scatter properties and thereafter subjected to two-color
nalysis with CD45-PE and CD14-FITC.
istology and immunohistochemistry. Thrombi formed
n stents were scraped off the stent surface, fixed in 10%
ormalin, and processed for paraffin embedding. Sections
2 ) were cut and stained with hematoxylin and eosin. For
mmunohistochemistry, sections were deparaffinized, pro-
essed for antigen retrieval as described by Pileri et al. (8),
nd incubated for 30 min with an anti-TF Mab (American
iagnostica). Thereafter the slides were incubated with
abbit antimouse immunoglobulins (Dako, Carpinteria,
alifornia) for 20 min, followed by 20 min with the
PAAP complex (Dako), which is a complex of mouse
lkaline phosphatase and antialkaline phosphatase Mab.
he color was then developed for 20 min with fucsin, after
hich the slides were counterstained with hematoxylin.
mage cytometry. TF staining was quantified by image
ytometry using a CCD monochromatic camera (Sony
C77CE, Kangawa-Ken, Japan) connected to a light mi-
roscope (Leitz GmbH, Wetzlar, Germany). Briefly, in
ach specimen the three most reactive areas of 0.5 mm2 were
elected with a 25 objective. Two images were collected
nder monochromatic light: the first at 530 nm, where TF
taining had the highest absorbance, and the second at 630
m, where nuclei stained most intensely. Nuclei were then
liminated from the image using an image processing
rocedure, allowing for the measurement of TF staining at
30 nm. For each specimen, results were expressed as
ntegrated optical density (IOD) units/mm2.
tatistics. Data are presented as mean values  SEM. A
mirnov-Kolmogorov test was used to test for normality.
ecause data were normally distributed, comparisons
mong the effects that different treatments (control, cH36,
nd 9E1 in the first set of experiments) or conditions (whole
lood, MRB, and MRB plus cH36 in the second set of
xperiments, etc.) had on the same individuals were per-
ormed using one-way analysis of variance for repeated
able 1. 125I-fibrin(ogen) Deposition (Mean Values  SEM) on
xperiments
irst set of experiments (10 cases)
Perfusion 1A Perfusion 1B
No stent Stent/saline
20,554  3,445 ng
econd set of experiments (6 cases)
Perfusion 2A Perfusion 2B
No stent Stent/WB
7,233  1,546 ng
hird set of experiments (6 cases)
Perfusion 3A Perfusion 3B
No stent/fPRP Stent/PPP S
129  7 ng
p  0.002 and †p  0.04 versus perfusion 1B; ‡p  0.01 and §p  0.01 versus pe
cH36  monoclonal antibody against tissue factor; MRB  monocyte-reduced b
filtered platelet-rich plasma; WB  whole blood.easures and Bonferroni’s test for all pairwise multiple aomparisons, as well as paired t test as appropriate. A p
alue 0.05 was considered statistically significant.
ESULTS
ematologic Parameters
ematologic parameters (hemoglobin, hematocrit, and
oth leukocyte and platelet counts) were within the normal
anges in all the donors. The mean activated clotting times,
easured at the beginning of the experiments, were 216 
0 s in the first set of experiments, 211  3 s in the second
et of experiments, and 207  4 s in the third set of
xperiments. Adjusted platelet count in the third set of
xperiments was 206,700  3,900/l.
roup 1
hrombus formation on stents. In group 1, in the absence
f a stent (circuit A), no visible thrombus formed in the
ubing. In the stent samples treated with saline (circuit B),
isible thrombus covered the stent surface, and in four of 10
xperiments free thrombus was also observed in the tubing.
hen blood was pretreated with anti-TF antibody (circuit
) or anti-P-selectin (circuit D) antibody, the visible
hrombus formed was reduced relative to the saline control
circuit B).
125I-Fibrin(ogen) deposition was 20,544  3,445 ng in
ircuit B (saline), 9,007  3,044 ng in circuit C (anti-TF),
nd 15,562  3,237 ng in circuit D (anti-P-selectin) (p 
.002; for multiple comparisons see Table 1). Figure 1
hows thrombus formation on stents exposed to blood
retreated with either saline or anti-TF.
istology and immunohistochemistry. The thrombi
ormed on stents perfused with blood pretreated with saline
circuit B) showed irregular areas of erythrocytes trapped in
fibrin network. Large and irregular platelet aggregates
ere scattered throughout the thrombi. Numerous granu-
ocytes and monocytes were deposited as irregular clusters
ithin the thrombi. Tissue factor staining was scattered
hroughout the thrombi, in close contact with the platelet
ts After 120 Min Perfusion in the Three Different Sets of
Perfusion 1C Perfusion 1D
Stent/cH36 Stent/9E1
9,007 3,044 ng* 15,562 3,237 ng†
Perfusion 2C Perfusion 2D
Stent/MRB Stent/MRB cH36
3,987  1,825 ng‡ 3,789  1,637 ng§
fusion 3C Perfusion 3D Perfusion 3E
PPP  cH36 Stent/fPRP Stent/fPRP  cH36
4  8 ng 1,339  223 ng 766  100 ng¶
n 2B; p  0.001 versus perfusion 3B; ¶p  0.01 versus perfusion 3D.
9E1  monoclonal antibody against P-selectin; PPP  platelet-poor plasma; fPRPSten
Per
tent/
13
rfusioggregates and intermingled with fibrin strands (Fig. 2). In
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usely positive for TF, whereas some neutrophils gave weak
nd irregular TF staining.
onocyte TF expression and platelet-monocyte aggre-
ates. In perfusion A (no stent), monocyte TF expression
id not significantly change throughout the perfusion (3.3
1% at baseline vs. 3.6  1% at 120 min; p  ns). When
aline-treated blood was perfused for 120 min in tubing
ontaining a stent (circuit B), however, monocyte TF
xpression increased significantly (3.5  1% vs. 17.9  5%;
 0.02) (Figs. 3A and 3B). In perfusions in which blood
igure 1. Thrombus formation after 120 min perfusion on stent surface
xposed to blood pretreated with either saline (control) or with a mono-
lonal antibody against tissue factor (cH36). Note the striking reduction of
hrombus formation on the stent in which blood was pretreated with cH36.
igure 2. Histologic assessment of thrombi formed on a stent surface
howing intense tissue factor staining (red). Monocytes (arrows) found inc
he thrombus displayed strong tissue factor staining, while granulocytes
isplayed weak and irregular staining. Original magnification 400.as pretreated with 9E1 (4 cases), at the end of the
erfusion there was a 46% reduction in monocyte TF
xpression compared with perfusion B (9.7 2% vs. 17.9
%, respectively; p  0.3). When monocytes were divided
nto those without and those with attached platelets, virtu-
lly all of the monocytes that stained positive for TF also
tained positive for the platelet marker CD42b (Figs. 3C
nd 3D). The percentage of monocytes that had platelets
ttached increased in both experiments where this was
nalyzed (pre-perfusion values 10% and 15%, post-
erfusion values 42% and 53%).
roup 2
hrombus formation on stents perfused with MRB. Pre-
reatment of blood with anti-CD14 beads reduced the
onocyte count by 93  1% as judged by flow cytometry
Figs. 4A and 4B). Stents perfused with MRB showed a
ignificant reduction in thrombus formation as compared
ith whole blood. Adding an anti-TF Mab to MRB
roduced only a small, nonsignificant reduction in
25I-fibrin(ogen).
Thus, 125I-fibrin(ogen) deposition on stents perfused
ith whole blood, MRB, and MRB  anti-TF were
,233  1,546 ng, 3,987  1,825 ng, and 3,789  1,637
g, respectively (p  0.006; for multiple comparisons see
able 1).
To determine whether the reduction of thrombus forma-
ion with MRB was accompanied by a decrease in TF
xpression in thrombi, we analyzed the thrombi immuno-
istochemically. As shown in Figure 5, thrombi formed in
erfusions with MRB had less TF staining than thrombi
ormed in perfusions with control whole blood (16,620 
,126 IOD/mm2 vs. 2,942  518 IOD/mm2, respectively,
 0.01). In addition, thrombi formed in perfusions with
RB showed markedly reduced numbers of monocytes.
ranulocytes, which gave weak and irregular TF staining,
ere more prominent in thrombi from MRB than in
hrombi from control whole blood.
roup 1
hrombus formation on stents perfused with PPP or
RP. When stents were exposed to PPP (circuit B), only a
mall amount of thrombus deposited on the stents (125I-
brin[ogen] deposition 129 7 ng) and cH36 did not affect
hrombus deposition (134  8 ng) (p  ns). With filtered
RP, thrombus formation was much greater than with PPP
125I-fibrin(ogen) deposition 1,340  223 ng; p  0.001),
ut much less than with whole blood. Pretreatment of PRP
ith cH36 significantly reduced 125I-fibrin(ogen) deposi-
ion (766  100 ng; p  0.01).
ISCUSSION
ur studies provide new data on the contributions of TF
nd monocytes to stent thrombosis. Utilizing a closed
ircuit, we demonstrated that perfusion of whole, heparin-
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Circulating Tissue Factor and Stent Thrombosis October 19, 2004:1570–7nticoagulated blood from normal controls for 120 min at
4 s1 consistently resulted in thrombus formation when a
tent was deployed in the circuit, but not when there was no
tent. The perfusion conditions were designed to simulate
he diameter and blood flow of a typical coronary artery after
tent placement. In our first series of experiments we
bserved that an antibody to TF decreased the amount of
brin(ogen) deposited in the thrombus by 56%. In the
econd series of experiments we observed that nearly deplet-
ng the blood of monocytes with an antibody to the
onocyte-specific antigen CD14 produced a 45% decrease
n fibrin(ogen) deposition. Adding an antibody to TF to the
lood nearly depleted of monocytes caused a further small
eduction in fibrin(ogen) deposition that was not statistically
ignificant. These data suggest that TF contributes to
hrombus formation and that monocytes are a major, but
erhaps not the sole, source of TF. To assess the potential
ole of other sources of TF, in the third series of experi-
ents we used PRP that was nearly devoid of leukocytes.
mall thrombi formed on stents and an antibody to TF
educed the thrombus by 43%, indicating that TF derived
rom platelets (9) and/or circulating microvesicles probably
lso contribute to stent thrombosis. Further support for the
mportance of monocytes in TF deposition came from the
igure 3. Tissue factor (TF) expression on monocyte membranes at baselin
ubjected to two-color analysis using TF-FITC as the abscissa and CD42b-
hat do not display TF staining. At the end of the perfusion (D) only moirect observation of decreased TF staining of thrombi mormed by blood nearly depleted of monocytes. We further
ound that after the perfusion more monocytes stained
ositive for the platelet-specific antigen CD42b and more
onocytes expressed TF. Moreover, the increased expres-
ion of TF was confined to monocytes that stained positive
or the platelet-specific antigen. This raises the possibility
hat platelet activation results in the attachment of platelets
o monocytes which, in turn, induces monocyte expression
f TF. This hypothesis is consistent with studies conducted
y others that indicate that platelet-monocyte aggregates
ncrease after percutaneous coronary interventions (10,11)
nd that both P-selectin (7,12,13) and CD40 ligand (7),
olecules expressed on the surface of activated but not
nactivated platelets, can stimulate monocyte synthesis of
F. Support for a role for P-selectin in stent-associated
hrombus formation comes from our additional studies
emonstrating that an antibody to P-selectin decreased TF
xpression on monocyte membranes and fibrin(ogen) dep-
sition in stent thrombi. These data, in turn, are consistent
ith prior studies by Palabrica et al. (14), who demonstrated
ecreased fibrin deposition in a Dacron graft implanted
ithin an arteriovenous shunt in nonhuman primates when
he animals were treated with an antibody to P-selectin.
uch antibodies may operate by decreasing platelet-
) and at the end of the perfusion (B). In two experiments monocytes were
s the ordinate: at baseline (C) there are some platelet-monocyte aggregates
es with attached platelets displayed TF staining.e (Aonocyte interactions (and the subsequent enhancement of
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eukocyte-derived microparticles containing both P-selectin
lycoprotein ligand-1 and TF to attach to activated platelets
xpressing P-selectin at the site of injury (15,16). Because
he effects of the antibody were observed very soon after
dministration, the latter mechanism is likely to have
ontributed, but it remains possible that the sustained effect
as due to the former mechanism. Nevertheless, the anti-P
electin Mab caused a partial reduction on monocyte TF
xpression, and its effect on thrombus formation was much
ess profound than the anti-TF Mab. This finding may be
he consequence of the existence of multiple pathways of
onocyte TF activation, which may be still operative even
n the presence of P-selectin blockade. Finally, our obser-
ations on the association of platelet-leukocyte aggregates
nd monocyte TF expression may explain why the presence
f circulating platelet-leukocyte aggregates after percutane-
igure 4. Whole blood before (A) and after (B) anti-CD14 bead addition
ubjected to all of the procedures used to deplete monocytes except for addin
ample (C) and the sample after the procedures (D).us coronary interventions in humans correlated with recur- tent ischemic events in an intriguing pilot study conducted
y Mickelson et al. (17).
Our current studies complement our previous studies of
tent insertion in nonhuman primates, where we demon-
trated that platelet adhesion and aggregate formation was
ccompanied by recruitment of monocytes and neutrophils
18). The platelet thrombus stained positive for TF antigen,
he neutrophils gave variably weak staining for TF, and the
onocytes stained strongly positive for TF. We also ob-
erved leukocytes adjacent to stent struts, an observation
onsistent with recent evidence of monocyte adhesion to
tent metal (19). In our previous study we could not,
owever, determine the source of TF that we observed in
he thrombi. Our new data reinforce the recent evidence
hat bloodborne TF can contribute to thrombus formation
nd extend those observations to thrombi formed on stents
4,20,21). Because there was no blood vessel in our system,
te in B the dramatic reduction of monocyte count. In controls that were
anti-CD14-coupled beads, no difference was noticed between the baseline. No
g thehe TF could not come from the blood vessel wall and thus
m
t
i
t
t
o
c
a
w
n
s
t
m
t
(
n
t
o
r
i
c
a
(
c
s
d
f
a
h
l
e
n
d
c
s
t
c
a
a
T
c
t
p
A
W
i
M
C
R
I
O
t
R
F
i agnifi
1576 Palmerini et al. JACC Vol. 44, No. 8, 2004
Circulating Tissue Factor and Stent Thrombosis October 19, 2004:1570–7ust be derived from the blood. Moreover, our data indicate
hat not only is TF deposited, but it plays an important role
n thrombus formation because an antibody to TF reduced
hrombus formation.
Among the proposed sources of blood TF are micropar-
icles derived from monocytes or neutrophils (15,16,20,22)
r an alternatively spliced form of TF (21). Although we
annot exclude the possibility that our antibody to CD14
lso depleted CD14-positive microparticles containing TF,
e and others (23) have not identified such microparticles in
ormal individuals, and although others have identified
mall numbers of such microparticles in normals (24,25),
here is uncertainty about the activity of TF in such
icroparticles (24). Platelets and platelet-derived micropar-
icles have also been proposed as sources of blood TF
9,24,25). Because we observed some TF in thrombi despite
early complete elimination of monocytes, we tried to assess
he contribution of platelets to blood TF in the near absence
f leukocytes. We observed that pretreating PRP with cH36
educed thrombus formation, thus suggesting TF is also
mportant in PRP-supported thrombus formation. We
ould not, however, differentiate between whether platelets
re themselves a source of TF, as suggested by Camera et al.
9), or rather serve as a nidus upon which microvesicle-
ontaining TF deposits after platelets form thrombi, as
hown by Rauch et al. (15). It is important, however, to
ifferentiate between TF antigen and activity. Thus, data
rom Diamant et al. (24) raise doubts about the functional
ctivity of TF in microparticles isolated from plasma, and it
as been postulated that interactions of platelets with
eukocytes or leukocyte-derived microparticles may be nec-
ssary to “de-encrypt” TF (26–28).
One limitation of our study is that we used blood from
ormal controls rather than patients with cardiovascular
isease. In preliminary experiments in patients with myo-
igure 5. Immunohistochemistry of thrombi formed on stents perfused w
n tissue factor staining (red) was observed compared with A. Original mardial infarction who were taking aspirin, we observedimilar or greater thrombus formation than with the con-
rols in this study. A separate study of patients is planned.
In conclusion, our data support an important role of
irculating TF in stent thrombosis. Monocytes appear to be
n important source of TF and it is possible that platelet
ctivation and platelet-monocyte interactions may enhance
F expression. Thus, the elements in the reverberating
ircuit among platelets, monocytes, and TF may be poten-
ial therapeutic targets, with specific inhibition of TF
articularly appealing.
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